{
  "pmcid": "5265688",
  "sha256": "5924cf20d18010a7574a38f419e305e610adeff64095dda7057bb2a228612d27",
  "timestamp_utc": "2025-11-09T22:45:50.990838+00:00",
  "model_used": "gpt-4o",
  "readability": {
    "flesch_kincaid": 7.986858080393766,
    "reading_ease": 54.21802707136999,
    "word_count": 212
  },
  "consort_scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial of Everolimus Plus Reduced-Dose Tacrolimus in Liver Transplant Recipients"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "randomised 1:1:1 to EVR + rTAC, TAC-WD, or TAC-C"
      },
      "Participants": {
        "score": 2,
        "evidence": "Participants were adult recipients of primary liver transplants from deceased donors, with an eGFR of 30 mL/min per 1.73 m² or greater."
      },
      "Intervention": {
        "score": 2,
        "evidence": "everolimus plus reduced-dose tacrolimus (EVR + rTAC) compared to standard-dose tacrolimus (TAC-C)"
      },
      "Objective": {
        "score": 1,
        "evidence": "This international, randomised controlled trial evaluated the efficacy and renal outcomes of everolimus plus reduced-dose tacrolimus (EVR + rTAC) compared to standard-dose tacrolimus (TAC-C) in de novo liver transplant recipients."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was the composite of treated biopsy-proven acute rejection, graft loss, or death at 12 months."
      },
      "Randomisation_Allocation": {
        "score": 1,
        "evidence": "Randomisation was stratified by pretransplant HCV status and eGFR."
      },
      "Blinding": {
        "score": 3,
        "evidence": "The study was open-label"
      },
      "Number_Randomised": {
        "score": 1,
        "evidence": "Of 719 participants, 211 were from North America."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "the analysis was intention-to-treat"
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "At month 12, the composite efficacy endpoint was 10.9% for EVR + rTAC and 13.1% for TAC-C. Mean changes in eGFR favored EVR + rTAC at months 12 (+3.7 vs −4.5 mL/min per 1.73 m²; P = 0.032) and 24 (+2.7 vs −6.6 mL/min per 1.73 m²; P = 0.042)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the EVR + rTAC group, leading to higher discontinuation rates."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCT01204993."
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Novartis Pharmaceuticals."
      }
    },
    "total_score": 21,
    "max_score": 25
  }
}